entertainment -WSS

entertainment

author：knowledge 2025-08-12 06:43:20 - browse：39

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Chemotherapy drug shortage eases slightly but still widespread

WSS

FDA panel signals lack of confidence in Amgen cancer drug data

Phenylephrine and the overlooked value of the placebo effect

More tobacco lobbyists active in statehouses

Sana to lay off nearly a third of staff, de

Sana to lay off nearly a third of staff, de

Why Charlie Gard's case is so disturbing to Americans

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Bright Health sells Medicare Advantage business to Molina

Liquid biopsy for lung cancer is launched by Delfi

New air purifier tech could be key to improving indoor air quality

Getting Alzheimer's drug Leqembi to patients can be a challenge

Cancer drug shortages should be causing more outrage

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Duchenne breakthrough therapy leaves behind pioneering families

FDA rejects Alnylam's heart disease treatment over insufficient data

23andMe had bad news about my health. I wish a person had delivered it

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

focus

When women are denied an abortion, their children fare worse than peers

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Why age limits for politicians are a terrible idea

Sana to lay off nearly a third of staff, de

MassMutual is introducing free genetic testing for members

Liquid biopsy for lung cancer is launched by Delfi

hotspot

focus

hotspot

entertainment